Generic Name and Formulations:
Sulfacetamide sodium 10%, prednisolone acetate 0.2%; oph susp; contains benzalkonium chloride.
Indications for BLEPHAMIDE:
Ocular inflammation with infection.
Adults and Children:
<6yrs: not established. ≥6yrs: 2 drops every 4 hours and at bedtime or small amount of ointment 3–4 times daily and 1–2 times at night. May prolong dosing interval as condition improves; max 20mL or 8g per therapeutic course. Re-evaluate if no improvement after 2 days.
Ocular fungal, viral, or mycobacterial infections.
Corneal or scleral thinning: increased risk of perforation. Glaucoma. Severe dry eye. Purulent exudates may inactivate sulfonamides. Cataract surgery: may delay healing and increase bleb formation. May mask signs of infection. Monitor for secondary ocular infections (eg, fungal) and intraocular pressure in prolonged use (≥10 days). Discontinue if rash or hypersensitivity reactions occur. Avoid abrupt cessation. Pregnancy. Nursing mothers: not recommended.
Sulfonamide + steroid.
Incompatible with silver-containing preparations. Antagonized by PABA.
Ocular irritation, secondary ocular infections; rare: severe sulfonamide reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, blood dyscrasias). In prolonged use: increased IOP, cataracts, optic nerve damage.
Susp—5mL, 10mL; Oint—3.5g
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib
- Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC
- Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed